WO2009120815A9 - Therapeutic compositions and methods - Google Patents

Therapeutic compositions and methods Download PDF

Info

Publication number
WO2009120815A9
WO2009120815A9 PCT/US2009/038311 US2009038311W WO2009120815A9 WO 2009120815 A9 WO2009120815 A9 WO 2009120815A9 US 2009038311 W US2009038311 W US 2009038311W WO 2009120815 A9 WO2009120815 A9 WO 2009120815A9
Authority
WO
WIPO (PCT)
Prior art keywords
methods
therapeutic compositions
therapeutic
compositions
Prior art date
Application number
PCT/US2009/038311
Other languages
French (fr)
Other versions
WO2009120815A2 (en
Inventor
Jeffrey A. Gelfand
Timothy A. Brauns
Alexander Nivorozhkin
Alexey Elissev
Original Assignee
Boston Biocom, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biocom, Llc filed Critical Boston Biocom, Llc
Publication of WO2009120815A2 publication Critical patent/WO2009120815A2/en
Publication of WO2009120815A9 publication Critical patent/WO2009120815A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
PCT/US2009/038311 2008-03-26 2009-03-26 Therapeutic compositions and methods WO2009120815A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3974308P 2008-03-26 2008-03-26
US61/039,743 2008-03-26

Publications (2)

Publication Number Publication Date
WO2009120815A2 WO2009120815A2 (en) 2009-10-01
WO2009120815A9 true WO2009120815A9 (en) 2010-01-07

Family

ID=41114694

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/038311 WO2009120815A2 (en) 2008-03-26 2009-03-26 Therapeutic compositions and methods

Country Status (1)

Country Link
WO (1) WO2009120815A2 (en)

Also Published As

Publication number Publication date
WO2009120815A2 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
EP2475632A4 (en) Monochlorotrifluoropropene compounds and compositions and methods using same
IL210153A0 (en) Nutrigenomics methods and compositions
ZA201001300B (en) Antigen-asjuvant compositions and methods
IL212822A0 (en) Anti-cxcr1 compositions and methods
GB0819530D0 (en) Methods and compositions
IL218212A0 (en) Therapeutic methods and compositions
IL210559A0 (en) Novel compositions and methods
HUE037121T2 (en) Novel compositions and methods
EP2370815A4 (en) Anti-inflammatory compositions and methods
GB0721291D0 (en) Methods and compositions
GB0817585D0 (en) Novel compositions and methods
GB0719526D0 (en) Compositions and methods
EP2461870A4 (en) Therapeutic compositions and methods
GB0811250D0 (en) Methods and compositions
ZA201008384B (en) Lasalocid compositions and methods
WO2009120815A9 (en) Therapeutic compositions and methods
AU2014200650C1 (en) Anti-CXCR1 compositions and methods
AU2008904402A0 (en) Methods and compositions
AU2008903953A0 (en) Methods and compositions
AU2008904789A0 (en) Prophylactic and therapeutic compositions
AU2008906012A0 (en) Therapeutic compositions
AU2007904579A0 (en) Methods and compositions
AU2007900834A0 (en) Methods and compositions
AU2008904486A0 (en) Methods and compositions for skin necrosis
AU2010901846A0 (en) Therapeutic methods and compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09723652

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09723652

Country of ref document: EP

Kind code of ref document: A2